Jeremy G. Chadwick - Mar 1, 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Operating Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/4/2024, 06:16 PM
Previous filing
May 22, 2023
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Award $0 +13.4K +40.28% $0.00 46.8K Mar 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +80.5K $0.00 80.5K Mar 1, 2024 Common Stock 80.5K $43.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.
F2 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.